



ABN: 15 129 742 409

Completion of dorsaVi Ltd's Private Placement

Melbourne, Australia – 25 January 2017: dorsaVi Ltd (ASX: DVL (**dorsaVi** or **Company**)) has successfully completed the A\$2.0 million second tranche of its private placement today.

Background

dorsaVi announced on 13 December 2016 that it had received commitments from sophisticated and institutional investors to subscribe for 15,217,393 new fully paid ordinary shares in the Company (**New Shares**) at A\$0.46 per New Share to raise A\$7.0 million in two tranches (**Placement**).

dorsaVi announced on 19 December 2016 that it had allotted 10,869,565 New Shares to complete Tranche 1 of the Placement. A\$5.0 million was raised under Tranche 1.

Following the approval granted at an extraordinary general meeting of dorsaVi's shareholders held on Friday 20 January 2017, dorsaVi has today issued 4,347,828 New Shares at A\$0.46 per New Share under the second of the two tranches (**Tranche 2**) to complete the Placement. In accordance with the shareholder approval, these New Shares were issued to major shareholder Starfish Technology Fund II (Trust A and Trust B). Accordingly, the final A\$2.0 million of the Placement has now been raised under Tranche 2. The New Shares issued today will rank equally with the Company's existing ordinary shares.

About dorsaVi

dorsaVi (ASX:DVL) is an ASX company focused on developing innovative motion analysis device technologies for use in elite sports, occupational health and safety, and clinical applications. dorsaVi believes its wearable sensor technology enables – for the first time – many aspects of detailed human movement and position to be accurately captured, quantified and assessed outside a biomechanics lab, in both real-time and real situations for up to 24 hours.

Our technology has applications across three sectors:

- **Clinical:** ViMove is transforming the management of patients by providing an objective assessment, monitoring outside the clinic and immediate biofeedback. ViMove is currently used by medical and physiotherapy practices in Australia and the United Kingdom and is now available in the United States following FDA 510K clearance.
- **Elite Sports:** ViPerform is allowing coaches and medical teams managing elite athletes and teams to screen athletes and provide objective evidence for decisions on return to play, measure biomechanics and provide immediate biofeedback out on the field, tailor and track training programs and optimise technique and peak performance. ViPerform is being used by AFL and NRL clubs and the Australian Institute of Sport (AIS) in Australia. In the UK, Barclays Premier League (EPL), U.S. based sports clubs including the National Basketball Association (NBA) and the National Football League (NFL), and various Olympic teams and athletes internationally.

For personal use only

- OHS: We combine innovation, measurement and quality to reduce workplace incidents, costs, meet compliance and improve brand reputation. ViSafe enables employers to assess the risk of injury for employees as well as test the effectiveness of proposed changes to workplace design, equipment or methods based on objective evidence. ViSafe has been used by major corporations including Sodexo, London Underground, Vinci Construction, Crown Resorts, Caterpillar (US), Monash Health, Coles, Woolworths, Toll, Toyota, Orora (formerly Amcor), Crown and BHP Billiton. Australian Workplace Compliance delivers risk mitigation through compliance to OHS, Quality Management Systems, Company Policy and Process.

Further information is available at www.dorsavi.com.